Theravance Biopharma, Inc.
TBPH
$8.40
$0.010.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 64.38M | 63.19M | 62.02M | 61.51M | 57.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.38M | 63.19M | 62.02M | 61.51M | 57.42M |
| Cost of Revenue | 37.64M | 36.50M | 35.55M | 35.02M | 40.62M |
| Gross Profit | 26.74M | 26.69M | 26.47M | 26.49M | 16.80M |
| SG&A Expenses | 69.17M | 66.52M | 65.79M | 68.01M | 70.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.82M | 103.03M | 101.34M | 103.03M | 111.07M |
| Operating Income | -42.44M | -39.83M | -39.32M | -41.52M | -53.65M |
| Income Before Tax | -44.61M | -40.69M | -38.22M | -37.19M | -49.27M |
| Income Tax Expenses | 11.80M | 8.71M | 7.43M | 7.58M | 5.92M |
| Earnings from Continuing Operations | -56.42 | -49.40 | -45.65 | -44.77 | -55.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.42M | -49.40M | -45.65M | -44.77M | -55.19M |
| EBIT | -42.44M | -39.83M | -39.32M | -41.52M | -53.65M |
| EBITDA | -40.73M | -38.15M | -37.64M | -39.39M | -50.84M |
| EPS Basic | -1.15 | -1.01 | -0.92 | -0.86 | -0.97 |
| Normalized Basic EPS | -0.51 | -0.47 | -0.45 | -0.44 | -0.51 |
| EPS Diluted | -1.15 | -1.01 | -0.92 | -0.86 | -0.97 |
| Normalized Diluted EPS | -0.51 | -0.47 | -0.45 | -0.44 | -0.51 |
| Average Basic Shares Outstanding | 195.37M | 195.48M | 198.81M | 206.74M | 221.39M |
| Average Diluted Shares Outstanding | 195.37M | 195.48M | 198.81M | 206.74M | 221.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
